Company Analysis

UroGen Pharma Ltd. (URGN)

Nasdaq: URGN · Pharmaceutical Preparations · Ra'Anana, IL · filing with the SEC since 2016
Grade5.2
◀ Past 5.1● Present 5.5▶ Future 4.8
1 est.

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

14 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to UroGen Pharma Ltd.’s names, not what it holds today.

Patents granted
14
14 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 1 in 2024 and 1 in 2023
Applications published
24
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
Medical technology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
UroGen Pharma Ltd. its own name
IL, as the owner printed on each patent
14 granted
9 published
UroGen Pharma Ltd. its own name
named as the applicant on its applications, in IL
0 granted
15 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Oct 14, 202512,440,568Material and method for treating internal cavitiesPharmaceuticalsUroGen Pharma Ltd.
Jun 24, 202512,336,979Material and method for treating cancerPharmaceuticalsUroGen Pharma Ltd.
Apr 8, 202512,268,745Material and method for treating internal cavitiesPharmaceuticalsUroGen Pharma Ltd.
Apr 1, 202512,263,245Immunomodulating treatments of body cavitiesPharmaceuticalsUroGen Pharma Ltd.
Dec 24, 202412,171,747Material and method for treating cancerPharmaceuticalsUroGen Pharma Ltd.
Feb 14, 202311,576,744Thermosensitive bio-adhesive hydrogel for removal of ureteral and renal stonesMedical technologyUroGen Pharma Ltd.
May 4, 202110,994,109Connectable catheterMedical technologyUroGen Pharma Ltd.
Sep 1, 202010,758,482Immunomodulating treatments of body cavitiesPharmaceuticalsUroGen Pharma Ltd.
Nov 12, 201910,471,150Material and method for treating internal cavitiesPharmaceuticalsUroGen Pharma Ltd.
Aug 7, 201810,039,832Material and method for treating internal cavitiesPharmaceuticalsUroGen Pharma Ltd.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 10, 20252025/0221929IMMUNOMODULATING TREATMENTS OF BODY CAVITIESPharmaceuticalsUroGen Pharma Ltd.
Jun 19, 20252025/0195665MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESPharmaceuticalsUroGen Pharma Ltd. · patent 12,440,568 granted from it
Jan 30, 20252025/0032409TREATMENT OF LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER WITH A THERMALLY GELLING PHARMACEUTICAL COMPOSITION CONTAINING MITOMYCINPharmaceuticalsUroGen Pharma Ltd.
Nov 21, 20242024/0382420IMMUNOMODULATING TREATMENTS OF BODY CAVITIESPharmaceuticalsUroGen Pharma Ltd. · patent 12,263,245 granted from it
Sep 12, 20242024/0299550MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESPharmaceuticalsUroGen Pharma Ltd. · patent 12,268,745 granted from it
Apr 4, 20242024/0108603MATERIAL AND METHOD FOR TREATING CANCERPharmaceuticalsUroGen Pharma Ltd. · patent 12,171,747 granted from it
Mar 28, 20242024/0100019COMPOSITIONS COMPRISING A THERMOREVERSIBLE HYDROGEL, AND HAVING AN EXTENDED IN-USE PERIODPharmaceuticalsUroGen Pharma Ltd.
Aug 3, 20232023/0241221MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESPharmaceuticalsUroGen Pharma Ltd.
Aug 3, 20232023/0241220MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESPharmaceuticalsUroGen Pharma Ltd.
Jul 27, 20232023/0233685MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIESPharmaceuticalsUroGen Pharma Ltd.
What it applied for, 2024 to 2025: Pharmaceuticals 7.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton URGN · research, not advice